Fisher Asset Management LLC Cuts Stake in Edwards Lifesciences Corporation $EW

Fisher Asset Management LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 41.1% during the 4th quarter, HoldingsChannel reports. The fund owned 145,645 shares of the medical research company’s stock after selling 101,775 shares during the period. Fisher Asset Management LLC’s holdings in Edwards Lifesciences were worth $12,416,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of EW. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. Hantz Financial Services Inc. lifted its holdings in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares during the period. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth about $29,000. Finally, Rakuten Securities Inc. lifted its holdings in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EW shares. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Evercore reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research note on Wednesday, April 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Stock Performance

NYSE EW opened at $86.55 on Thursday. The firm has a market capitalization of $49.83 billion, a P/E ratio of 46.04, a P/E/G ratio of 2.19 and a beta of 0.87. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $88.28. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The business’s 50-day simple moving average is $81.62 and its 200-day simple moving average is $82.97.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 105,829 shares of company stock valued at $8,799,770. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.